Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps1-02-02 | Graves’ Disease | ETA2023

Predetermined vs calculated 131I activity for the treatment of patients with graves’ disease: which is the best?

Arcidiacono Francesco , Barca Ignazio , Prinzi Antonio , Scuto Andrea , Volpe Salvatore , Piticchio Tommaso , Malandrino Pasqualino , Frasca Francesco , Belfiore Antonino

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...

ea0092ps3-29-03 | Treatment 2 | ETA2023

TKIS for advanced thyroid cancer increase tsh levels in thyroidectomized patients: A meta-analysis

Piticchio Tommaso , Belfiore Antonino , Malandrino Pasqualino , Trimboli Pierpaolo , Gambero Federica , Scuto Andrea , Volpe Salvatore , Di Benedetto Guenda , Dario Tumino , Le Moli Rosario , Privitera Grete , Pulvirenti Alfredo , Frasca Francesco

Background: Tyrosine kinase inhibitors (TKIs) are modern antineoplastic molecules widely used in the medical treatment of many cancers including iodine refractory differentiated thyroid carcer (DTC) and advanced medullary thyroid cancer (MTC). In patients with thyroid gland, TKIs frequently cause a destructive and/or autoimmune thyroiditis with consequent hypothyroidism. However, authors have reported unexpected TSH increase or hypothyroidism even in patients with total thyroi...